In many ways, the U.S. today has less control over its economy than ever before. We have been a country richly endowed with resources, but we’ve run so hot for so long, and been so profligate, that much of that initial endowment is gone. This could… Read More

Southern Copper is strongly positioned Read More

Novo leads the way with game-changing drugs Read More

McKesson and DaVita look fine Read More

A focus on rare autoimmune diseases Read More

The horrific events in the Mideast are the latest geopolitical developments demonstrating how times have changed for the U.S. economy. The Fed, once the key player when assessing market trends, is no longer proactive but must simply react to forces beyond its control. The most important of these relates to… Read More

This month, Amgen (NSDQ: AMGN) (Income/Value Portfolio) completed its acquisition of Horizon Therapeutics, which specializes in developing treatments for rare autoimmune disorders. The acquisition (for almost $28 billion, all cash), follows last year’s $4 billion purchase of Chemocentryx, another autoimmunology specialist, making plain where Amgen’s focus is. The road to… Read More

Companies that seem to get it Read More